# **Appendix - Table of Contents**

METHODS
APPENDIX TABLES
Table 1: Changes to HES Provider Codes Due to Splitting and Mergers Between NHS Hospital Trusts, April 2010 to March 2017
Table 2: The RECORD Statement: A checklist of items that should be reported in observational studies using routinely collected health data, and the page on which each checklist item appears
Table 4: Number of Acute/General Medical Admissions in 135 Acute Care NHS Hospital Trusts, England, April 2010 to March 2017
Table 5: Clinical Classifications Software (CCS) Diagnosis Group Identified among Acute/General Medical Admissions in 135 Acute Care NHS Hospital Trusts, England, April 2010 to March 201721
Table 6: Random effects meta-regression of the association between the adjusted probability of death within 30 days of admission (in/out of hospital) and different metrics of hospital-level antibiotic use, among 36,124,372 acute/general medicine admissions to 135 NHS acute care hospital Trusts, April 2010 – March 2017
Table 7: Random effects meta-regression of the association between the adjusted probability of death within 30 days of admission (in/out of hospital) and different metrics of hospital-level antibiotic use, among a more narrowly defined cohort of 19,023,144 acute/general medicine admissions, April 2010 – March 2017
Table 8: Random effects meta-regression of the association between the adjusted probability of death within 30 days of admission (in/out of hospital) and different metrics of hospital-level antibiotic use, among 16,492,990 acute/general medicine admissions, 01/April/2014 – 31/March/201725
Table 9: Random effects meta-regression of the association between the adjusted probability of death within 14 days of admission (in/out of hospital) and different metrics of hospital-level antibiotic use, among 36,124,372 acute/general medicine admissions, 01/April/2010 – 31/March/201726
Table 10: Random effects meta-regression of the association between the adjusted probability of non-elective re-admission within 30 days of discharge and different metrics of hospital-level antibiotic use, among 34,427,698 acute/general medicine admissions discharged alive, 01/April/2010 – 28/February/2017
APPENDIX FIGURES
Figure 1: Order of Data Cleaning Steps Followed to Derive Analytic Cohort28
Figure 2: Non-linear Relative Risks of Death Within 30 Days of Admission (In/Out of Hospital)  Among Model Covariates Fit As Natural Cubic Splines29
Figure 3: Top 10 Most Commonly Used Antibiotics as a Fraction of Total DDDs Within Each of 135 NHS Acute Care Hospital Trusts (2016), Ranked by Amoxicillin/Clavulanic Acid30
Figure 4: Random Effects Meta-Regression of the Association Between Adjusted Probability of Death Within 30 Days of Admission (In/Out of Hospital) and Hospital-level Antibiotic Use32
4.1a) Total DDDs/1,000 bed-days
4.1b) Total DDDs/1,000 admissions
4.2a) Inpatient DDDs/1,000 bed-days33
4.2b) Inpatient DDDs/1,000 admissions
4.3a) Outpatient DDDs/1,000 bed-days

	4.3b) Outpatient DDDs/1,000 admissions	34
	4.4a) Oral DDDs/1,000 bed-days	35
	4.4b) Oral DDDs/1,000 admissions	35
	4.5a) Parenteral DDDs/1,000 bed-days	36
	4.5b) Parenteral DDDs/1,000 admissions	36
	4.6a) Narrow-spectrum DDDs/1,000 bed-days	37
	4.6b) Narrow-spectrum DDDs/1,000 admissions	37
	4.7a) Broad-spectrum DDDs/1,000 bed-days	38
	4.7b) Broad-spectrum DDDs/1,000 admissions	38
	4.8a) Access DDDs/1,000 bed-days	39
	4.8b) Access DDDs/1,000 admissions	39
	4.9a) Watch DDDs/1,000 bed-days	40
	4.9b) Watch DDDs/1,000 admissions	40
	4.10a) Access or Watch (depending on indication) DDDs/1,000 bed-days	41
	4.10b) Access or Watch (depending on indication) DDDs/1,000 admissions	41
	4.11a) Reserve DDDs/1,000 bed-days	42
	4.11b) Reserve DDDs/1,000 admissions	42
	4.12a) Piperacillin/tazobactam and meropenem DDDs/1,000 bed-days	43
	4.12b) Piperacillin/tazobactam and meropenem DDDs/1,000 admissions	43
RE	FERENCES	45

#### **METHODS**

### **Terminology**

A "Trust" is an organisational unit within the NHS that may provide hospital services, community services, or may act as a commissioner when sub-contracting care to other health services providers. In this study, the term "Trust" is synonymous with acute hospital.

A provider "spell" reflects a period of care in a single hospital, starting at the time of admission and ending at the time of discharge, death, or transfer out. Within a spell an "episode" reflects a defined period of care under a consultant. Thus, a spell comprises one or more episodes.(1) Episodes which share a patient identification number (HESID), admission date, provider code, and hospital provider spell number together compose a provider spell.(2)

Bed days reported by PHE(3) are collected by consultant main specialties and include either beds that are occupied at midnight on wards that are open overnight or beds occupied by at least one day-case on day-only wards. The reporting excludes beds that have been commissioned from non-NHS providers, beds designated solely for use by well infants, critical care beds, and residential care beds.(4)

#### **Identifying spells**

Study authors Eric P. Budgell and A. Sarah Walker had access to the raw HES data extracts, which included 123,079,071 consultant episodes. Episodes were dropped if identified as perfect duplicates (n=14,672,193), duplicates across all fields except episode identifier number (epikey) (n=22,196), if admitted before 01 April 2009 (n=139,179), missing an admission date (n=5,804), missing a HESID (n=70,619), or missing a hospital provider spell number (n=340). Among the remaining 108,168,740 episodes, 88,718,419 unique spells were identified in 15,708,476 patients between 1 April 2009 and 31 March 2017. The remaining cleaning steps are outlined in Appendix Figure 1.

## Imputing missing data

In the final analytic cohort (n=36,124,372 spells), the nearest preceding or subsequent spells were used to impute missing IMD score (n=83,642) (patients missing IMD score in all spells had already been dropped). Missing sex (n=1,547) was imputed to the mode (female), as was missing admission method (n=3,832) (mode: elective and other non-emergency), and missing admission source (n=36,848) (mode: usual/other place of residence).

## Preparation of antibiotic data

Only systemic antibiotics were included in DDD estimates; thus eye drops and other topical agents (gels, creams) were excluded, as were pessaries, beads, bone cement, and non-absorbed antibiotics such as neomycin (ATC code: J01GB05). A small number of other agents were excluded for miscellaneous reasons, including methenamine (this is metabolised to formalin to suppress urinary tract infections, but is not an antibiotic), demeclocycline (this is an antibiotic but is used primarily to treat hyponatremia), and colistin (ATC code: A07AA10) which was very rarely used. Rifabutin was excluded due to its probable use in tuberculosis treatment; other antibiotics used primarily in the treatment of tuberculosis were excluded in advance by PHE.

Broad-spectrum antibiotics were defined as co-amoxiclav, piperacillin/tazobactam, second (e.g. cefuroxime), third (e.g. ceftriaxone, ceftazidime), fourth (e.g. cefepime) or fifth (e.g. ceftobiprole) generation cephalosporins, cephalosporin-beta-lactamase inhibitor combinations (e.g. ceftazidime-

avibactam, ceftolozane-tazobactam), carbapenems, quinolones, azithromycin, tigecycline, aztreonam, telithromycin, and polymyxins (Appendix Table 3). Antibiotics not meeting this definition were classified as narrow-spectrum.

#### Preparation of HES data and model selection

Following HES guidance,(5) the primary diagnosis code was used to derive 142 CCS diagnosis groups, while secondary diagnosis fields were used to derive a Charlson Comorbidity Index. Following an approach reported in previous analyses,(6) the CCS groups were then aggregated into 43 subgroups based on clinical feedback, and categories with low (<0.5%) observed mortality were collapsed into a single 'low risk' group. To improve model stability, the smallest remaining categories (cumulatively accounting for 6.11% of all spells) were then collapsed into two 'other' categories with 30-day mortality risk above and below the overall mortality risk, respectively. This process yielded a total of 29 CCS categories shown in Appendix Table 5. A binary indicator of immunosuppression was defined from secondary diagnosis code indicating metastatic cancer, severe liver disease, or HIV.

The IMD score was provided by NHS Digital based on the 2010 English index of deprivation associated with the Super Output Area Level of the patient's residence (postal codes were not collected); a more recent 2015 deprivation index is available, but HES continues to use the 2010 index.(5)

The categories used to define primary admission specialty were based on the descending prevalence of consultant specialties. First, spells with a main specialty code (HES: mainspef) or treatment specialty code (HES: tretspef) of 300 in the first or second consultant episode were defined as acute/general medicine. If this code was not present then the next most common admission specialty code was used. This logic was then repeated for each of the specialties included in the sample population (Figure 1, main text). To improve model stability, individual admission specialties comprising <1 million spells were grouped as "other", including endocrinology, diabetic medicine, acute internal medicine, respiratory medicine, infectious diseases, neurology, and rheumatology. In the primary analysis (n=36,124,372 spells), Royal Surrey NHS Foundation Trust had very few admissions (n=182) in the reference group of admission specialty (general medicine) and yielded the highest adjusted probability estimate for 30-day mortality (2.96%, 95% CI: 0.84,5.07). In meta-regression models this point estimate was therefore truncated down to the 99<sup>th</sup> percentile.

Ethnic categories (HES: ethnos) were defined as white (ethnos="British (White)", "Irish (White)", "Any other White background"), Asian (ethnos="Indian (Asian or Asian British)", "Pakistani (Asian or Asian British)", "Bangladeshi (Asian or Asian British)", "Any other Asian background", "Chinese (other ethnic group)"), black (ethnos="Caribbean (Black or Black British)", "African (Black or Black British)", "Any other Black background"), other (ethnos="White and Black Caribbean (Mixed)", "White and Black African (Mixed)", "White and Asian (Mixed)", "Any other Mixed background", "Any other ethnic group"), and unknown (ethnos="Not stated", "Not known"). Admission method categories (HES: admimeth) were defined as A&E (admimeth="2A", "21"), elective and other non-emergency (admimeth="11", "12", "13", "25", "31", "32", "81", "82", "83"), or emergency via GP or other source ("22", "23", "24", "28", "2B", "2D"). Admission source categories (HES admisorc) were defined as usual/other place of residence (admisorc="19", "29", "39", "66", "79") or NHS general ward/other care provider (admisorc="49", "51", "52", "53", "54", "65", "85", "87", "88"). The definition of each admission method and source category can be found in the HES Admitted Patient Care data dictionary.(7) Intended management was collected from HES but not included in regression models as it was unknown in 53.8% (n=19,417,403) of spells.

Patient classification categories were collapsed, with "Regular night attender" (n=1,113) being combined with "Regular day attender", "Mothers and babies using only delivery facilities" (n=168) being combined

with "Ordinary admission", and "Day-case admission" being combined with "Ordinary admission" if length of stay was >1 day (n=92).

If no outcomes were observed in one of the categories of a model factor (for example, no deaths among "regular day attenders"), the category was combined with the mode for that hospital Trust only. One exception was the "low risk" category of CCS group which was combined with the "Other" CCS group where mortality risk was below the overall risk (Appendix Table 5). In the primary analysis of 30-day mortality, such changes were made to 13/135 hospital Trusts and affected only one or two variables where categories concerned had very few admissions (often <0.1% of total admissions within the hospital).

Substantial collinearity was observed between alternate measures of previous hospital exposure, including the number of overnight admissions in the past year versus ever (Spearman's  $\rho$ : 0.73, p<0.0001) and the number of complex overnight admissions in the past year versus ever (Spearman's  $\rho$ : 0.75, p<0.0001). Each measure was assessed in a single model adjusting for all hospital Trusts, as was a binary indicator for ever having had a complex admission in the past year. Factors were selected for inclusion in multivariate models based on minimizing the BIC in these single models, and included overnight admissions in the past year and any complex admission in the past year.

To improve model stability, age at admission (years), Charlson Comorbidity Index, and overnight admissions in the past year were truncated at the 99<sup>th</sup> percentile. To account for non-linear effects of continuous variables, age, Charlson score, IMD score, and overnight admissions in the past year were fit as natural cubic splines (Stata command: mkspline, cubic), as they lowered BIC of models adjusting for all hospital Trusts. The number of knots (up to six) was chosen based on BIC, with five Harrell knots(8) chosen for age, six Harrell knots chosen for IMD score, six knots chosen for Charlson score (with knots placed at the at the 10th, 35th, 50th, 65th, 80th, and 90th percentile of the non-zero distribution), and three knots chosen for overnight admissions in the past year (with knots placed at the 10th, 70th, and 90th percentile of the non-zero distribution) (Appendix Figure 2). In the latter two covariates, placement of knots at fixed intervals was not possible due to limited variation in the truncated distributions. Adjusted models retained the same number of knots, which remained significant (p<0.001) and were visualized to assess over-fitting.

Nine interaction terms included in previous analyses(6) were added individually to a single multivariate model including all hospital Trusts and found to significantly improve the model fit (lowered the BIC); these interactions were between age and Charlson score, admission method and calendar year, admission method and overnight admissions in the past year, admission specialty and overnight admissions in the past year, admission specialty and Charlson score, overnight admissions in the past year and Charlson score, ever had a complex overnight admission in the past year and overnight admissions in the last year and overnight admissions in the last year.

The 16 admission factors in Table 1 were adjusted for irrespective of statistical significance to ensure the best possible adjustment for case-mix when deriving marginal effects, rather than to assess the relative effect of factors within models, and these admission factors have been identified as predictors of mortality in previous large studies.(6,9) For the same reason, each model was fitted to data from each hospital Trust individually. To account for patients with repeated hospital admissions (observations which are not independent), a clustered version of the sandwich estimator was used, which affects the variance—covariance matrix of the estimators (including standard errors) but has no impact on estimated coefficients, thus yielding wider confidence bounds around point estimates than would be observed if all observations were assumed to be independent.

All marginal effects were derived in Stata using "nlcom" for nonlinear combination of estimators; results were compared with output from Stata's "margins" command, which was computationally slow but

provided a reference check on all estimates and their standard errors. Random effects meta-regression was then performed in Stata using the "metareg" command.(10) This method is an extension of standard random effects meta-analysis(11–14) and is often performed on study-level summary data, allowing the underlying sources of statistical heterogeneity in effect estimates across hospital Trusts to be explored. The use of random-effects models accounts for the variance of hospital-level effects and residual (unexplained) sources of between-hospital heterogeneity, assuming hospital-level effects follow a normal distribution around the linear predictor.

For the primary mortality analysis, marginal effects were also derived using logistic regression.(15) These were very highly correlated (Spearman's  $\rho$ : 0.9992, p<0.0001) and similar in magnitude to estimates derived from Poisson models, so were not considered further.

#### **APPENDIX TABLES**

Table 1: Changes to HES Provider Codes Due to Splitting and Mergers Between NHS Hospital Trusts, April 2010 to March 2017

Old provider code <sup>i</sup>	Updated provider code	Financial year when change occurred
-		change occurred
Worthing and Southlands Hospitals NHS		
Trust (RPL), and Royal West	Western Sussex Hospitals NHS	
Sussex NHS Trust (RPR)	Foundation Trust (RYR)	2010/11
Nuffield Orthopaedic Centre NHS Trust	Oxford University Hospitals NHS	
(RBF)	Foundation Trust (RTH)	2012/13
Winchester and Eastleigh Healthcare	Hampshire Hospitals NHS	
NHS Trust (RN1)	Foundation Trust (RN5)	2012/13
	Central Manchester University	
	Hospitals NHS Foundation Trust	
Trafford Healthcare NHS Trust (RM4)	(RW3)	2012/13
Scarborough and North East Yorkshire	York Teaching Hospital NHS	
Health Care NHS Trust (RCC)	Foundation Trust (RCB)	2012/13
Newham University Hospital NHS Trust		
(RNH), and Whipps Cross University		
Hospital NHS Trust (RGC), and Barts		
and The London NHS Trust (RNJ)	Barts Health NHS Trust (R1H)	2013/14
South London Healthcare NHS Trust	King's College Hospital NHS	
(RYQ)	Foundation Trust (RJZ) ii	2014/15
Mid Staffordshire NHS Foundation Trust	University Hospitals of North	
(RJD)	Midlands NHS Trust (RJE) ii	2014/15
Ealing Hospital NHS Trust (RC3), and		
North West London Hospitals NHS	London North West Healthcare NHS	
Trust (RV8)	Trust (R1K)	2015/16
Barnet and Chase Farm Hospitals NHS	Royal Free London NHS Foundation	
Trust (RVL)	Trust (RAL)	2015/16
Royal National Hospital for Rheumatic	Royal United Hospitals Bath NHS	
Diseases NHS Foundation Trust (RBB)	Foundation Trust (RD1)	2015/16
Heatherwood and Wexham Park	Frimley Health NHS Foundation	
Hospitals NHS Foundation Trust (RD7)	Trust (RDU)	2015/16
West Middlesex University Hospital	Chelsea and Westminster Hospital	
NHS Trust (RFW)	NHS Foundation Trust (RQM)	2015/16
Torbay and Southern Devon Health and	Torbay and South Devon Health Care	
Care NHS Trust (R1G)	NHS Foundation Trust (RA9)	2015/16

<sup>&</sup>lt;sup>i</sup> A mapping from old to new provider codes is available from NHS Digital(16). Note other Trust mergers and splitting occurred during the study timeframe (for example, RG3, RGZ, and RG2 merged to form RYQ in 2010/11), but are excluded from this table because these provider codes were either already updated in our raw data files or not included. Note some provider codes have changed since the close of the HES data in March 2017 (for example, between April 2017 and October 2019 all of the following provider codes had changed due to Trust mergers: RE9, RGQ, RJF, RLN, RNL, RQ6, RQQ, RR1, RW3).

<sup>&</sup>lt;sup>ii</sup> RYQ split into RJZ, RJ2, and RPG. RJD split into RJE and RL4. Since RJZ and RJE had the most admissions per year(17), these provider codes were assumed.

Table 2: The RECORD Statement: A checklist of items that should be reported in observational studies using routinely collected health data, and the page on which each checklist item appears

	STROBE items	RECORD items	Page where checklist item appears
Title and Abstract	, 22222		, appense
	(a) Indicate the study's design with a	The type of data used should be specified in the title	
	commonly used term in the title or the	or abstract. When possible, the name of the databases	
	abstract.	used should be included.	p.3
	(b) Provide in the abstract an informative and	If applicable, the geographic region and time frame	
	balanced summary of what was done and what	within which the study took place should be reported	
	was found.	in the title or abstract.	p.3
			N/ A – linkage of HES data
			with death information from
			ONS was performed by
		If linkage between databases was conducted for the	NHS Digital before data
		study, this should be clearly stated in the title or	were shared with the study
		abstract.	team, as described on p.6.
Introduction			
Background	Explain the scientific background and		
and rationale	rationale for the investigation being reported.		p.5
	State specific objectives, including any		
Objectives	prespecified hypotheses.		p.6
Methods			•
	Present key elements of study design early in		
Study Design	the paper.		p.6-7
	Describe the setting, locations, and relevant		
	dates, including periods of recruitment,		
Setting	exposure, follow-up, and data collection.		p.6-7
	(a) Cohort study: Give the eligibility criteria		
	and the sources and methods of selection of	The methods of study population selection (such as	
	participants. Describe methods of follow-up.	codes or algorithms used to identify subjects) should	
Participants	Case-control study: Give the eligibility criteria	be listed in detail. If this is not possible, an	p.6 and Figure 1

	and the sources and methods of case	explanation should be provided. RECORD of	
	ascertainment and control selection. Give the	individuals with linked data at each stage.	
	rationale for the choice of cases and controls.		
	Cross-sectional study: Give the eligibility		
	criteria and the sources and methods of		
	selection of participants.		
	(b) Cohort study: For matched studies, give	Any validation studies of the codes or algorithms	
	matching criteria and number of exposed and	used to select the population should be referenced. If	
	unexposed. Case-control study: For matched	validation was conducted for this study and not	
	studies, give matching criteria and the number	published elsewhere, detailed methods and results	
	of controls per case.	should be provided.	N/A
			Hospital-level antibiotic
			data was merged with HES
			data using hospital name, as
			discussed on p.6-7. Hospital
			names were updated in
		If the study involved linkage of databases, consider	advance of the merge to
		use of a flow diagram or other graphical display to	account for hospital
		demonstrate the data linkage process, including the	mergers/splitting as outlined
		number of individuals with linked data at each stage.	in Appendix Table 1.
	Clearly define all outcomes, exposures,	A complete list of codes and algorithms used to	Main text: p.7 and p.10,
	predictors, potential confounders, and effect	classify exposures, outcomes, confounders, and effect	Table 1.
	modifiers. Give diagnostic criteria, if	modifiers should be provided. If these cannot be	Supplementary appendix:
Variables	applicable.	reported, an explanation should be provided.	p.2-4, Tables 3-5.
v arrabics	For each variable of interest, give sources of	reported, an explanation should be provided.	p.2 -, 1 auto 5-5.
	data and details of methods of assessment		Main text: p.6-7, and p.10,
	(measurement). Describe comparability of		Table 1
Data sources /	assessment methods if there is more than one		Supplementary appendix:
measurement	group.		p.2-4, Tables 1 and 3-5.
	0		Main text: p.6, p.13
	Describe any efforts to address potential		Supplementary Appendix:
Bias	sources of bias.		p.4
			Supplementary Appendix:
Study size	Explain how the study size was arrived at.		p.2 and Figure 1

			Main text: p.7 and p.10,
	Explain how quantitative variables were		Table 1
Quantitative	handled in the analyses. If applicable, describe		Supplementary Appendix:
variables	which groupings were chosen and why.		p.2-5
			Main text: p.7 and p.10
Statistical	(a) Describe all statistical methods, including		Supplementary Appendix:
methods	those used to control for confounding.		p.3-5
			Main text: p.7 and p.10
	(b) Describe any methods used to examine		Supplementary Appendix:
	subgroups and interactions.		p.4
			Supplementary Appendix:
	(c) Explain how missing data were addressed.		p.2
	(d) Cohort study: If applicable, explain how		
	loss to follow-up was addressed. Case-control		
	study: If applicable, explain how matching of		
	cases and controls was addressed. Cross-		
	sectional study: If applicable, describe		
	analytical methods taking account of sampling		
	strategy.		N/A
	(e) Describe any sensitivity analyses.		p.10-12
Data access and		Authors should describe the extent to which the	
cleaning		investigators had access to the database population	p.6
methods	N/A	used to create the study population.	
			Main text: p.6-7
		Authors should provide information on the data	Supplementary Appendix:
		cleaning methods used in the study.	p.2-4 and Figure 1
			Hospital-level antibiotic
			data was merged with HES
			data using hospital name, as
			discussed on p.6-7. Hospital
			names were updated in
		State whether the study included person-level,	advance of the merge to
		institutional-level, or other data linkage across two or	account for hospital
		more databases. The methods of linkage and methods	mergers/splitting as outlined
Linkage	N/A	of linkage quality evaluation should be provided.	in Appendix Table 1.
Results			

		Describe in detail the selection of the persons	
	(a) Report the numbers of individuals at each	included in the study (i.e., study population	
	stage of the study (e.g., numbers potentially	selection), including filtering based on data quality,	
	eligible, examined for eligibility, confirmed	data availability, and linkage. The selection of	
	eligible, included in the study, completing	included persons can be described in the text and/or	Supplementary Appendix:
Participants	follow-up, and analysed).	by means of the study flow diagram.	p.2 and Figure 1
	(b) Give reasons for nonparticipation at each		Supplementary Appendix:
	stage.		p.2 and Figure 1
			Supplementary Appendix:
	(c) Consider use of a flow diagram.		Figure 1
	(a) Give characteristics of study participants		
	(e.g., demographic, clinical, and social) and		
Descriptive	information on exposures and potential		
data	confounders.		p.7 and 10, Table 1
	(b) Indicate the number of participants with		Supplementary Appendix,
	missing data for each variable of interest.		p.2
	(c) Cohort study: summarise follow-up time		
	(e.g., average and total amount).		p.7
	Cohort study: Report numbers of outcome		
	events or summary measures over time. Case-		
	control study: Report numbers in each		
	exposure category or summary measures of		
	exposure. Cross-sectional study: Report		Main text: p.11-12, Figure
	numbers of outcome events or summary		3-4
Outcome data	measures.		
			Table 1 displays factors that
	(a) Give unadjusted estimates and, if		were adjusted for in models
	applicable, confounder-adjusted estimates and		of mortality and
	their precision (e.g., 95% confidence interval).		readmission. Figure 3-4
	Make clear which confounders were adjusted		present results of meta-
	for and why they were included. (b) Report		regression models, as do
	category boundaries when continuous		Supplementary Appendix
	variables were categorized. (c) If relevant,		Tables 6-10.
	consider translating estimates of relative risk		A condinad in
Main no14 -	into absolute risk for a meaningful time		As outlined in
Main results	period.		Supplementary Appendix

			p.4, marginal effects were derived from models containing 16 admission factors, irrespective of statistical significance, to ensure the best possible adjustment for case-mix, rather than to assess the relative effect of factors within models. Up to 135 hospital-specific models were fit for each outcome analysed. For these reasons, univariate effects are not presented.
Other analyses	Report other analyses done—e.g., analyses of subgroups and interactions and sensitivity analyses		p.10-12, Figure 3
Discussion	unaryses		p.10 12, 11guic 3
Key results	Summarise key results with reference to study objectives.		Main text: p.10-12, 14, Figure 3-4 Supplementary Appendix: Tables 6-10
Limitations	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	p.13-14
Interpretation	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.  Discuss the generalisability (external validity)		p.3-4 and 12-14, Figure 3
Generalisability	of the study results.		p.12 and 14

Other			
information			
	Give the source of funding and the role of the funders for the present study and, if		
	applicable, for the original study on which the		
Funding	present article is based.		p.16
Accesibility of			
protocol, raw			
data, and		Authors should provide information on how to access	
programming		any supplemental information such as the study	
code	N/A	protocol, raw data, or programming code.	p.15

N/A = Not applicable

Table 3: Classification of Antibiotics into Broad-spectrum, Access, Watch, and Reserve Categories, Adapted by Public Health England from the World Health Organization 2017 Essential Medicines List

Antibiotics	ATC index code 2020	Classified as broad-spectrum	AWaRe England category
Amikacin	J01GB06	No	Watch
Amoxicillin	J01CA04	No	Access
Amoxicillin/Clavulanic Acid	J01CR02	Yes	Watch
Ampicillin	J01CA01	No	Access
Ampicillin/Flucloxacillin	J01CA51	No	Access
Ampicillin/Flucloxacillin	J01CR50	No	Access
Avibactam/Ceftazidime	J01DD52	Yes	Reserve
Azithromycin	J01FA10	No	Access or Watch <sup>1</sup> (depending on indication)
Aztreonam	J01DF01	Yes	Reserve
Cefaclor <sup>2</sup>	J01DC04	No	Watch
Cefadroxil	J01DB05	No	Watch
Cefalexin	J01DB01	No	Watch
Cefixime	J01DD08	Yes	Access or Watch (depending on indication)
Cefotaxime	J01DD01	Yes	Access or Watch (depending on indication)
Cefpodoxime Proxetil	J01DD13	Yes	Watch
Cefradine	J01DB09	No	Watch
Ceftaroline Fosamil	J01DI02	Yes	Reserve
Ceftazidime	J01DD02	Yes	Watch
Ceftobiprole Medocaril	J01DI01	Yes	Reserve
Ceftolozane/Tazobactam	J01DI54	Yes	Reserve
Ceftriaxone	J01DD04	Yes	Access or Watch (depending on indication)
Cefuroxime	J01DC02	Yes	Watch
Cefuroxime Axetil	J01DC02	Yes	Watch
Chloramphenicol	J01BA01	No	Watch
Cilastatin/Imipenem	J01DH51	Yes	Reserve
Ciprofloxacin	J01MA02	Yes	Access or Watch (depending on indication)
Clarithromycin	J01FA09	No	Access or Watch (depending on indication)
Clindamycin	J01FF01	No	Watch
Colistin	J01XB01	Yes	Reserve
Dalfopristin/Quinupristin	J01FG02	No	Watch
Daptomycin	J01XX09	No	Reserve
Doripenem	J01DH04	Yes	Reserve
Doxycycline	J01AA02	No	Access

Antibiotics	ATC index code 2020	Classified as broad-spectrum	AWaRe England category
Ertapenem	J01DH03	Yes	Reserve
Erythromycin	J01FA01	No	Watch
Fidaxomicin	A07AA12 <sup>3</sup>	No	Watch
Flucloxacillin	J01CF05	No	Access
Fosfomycin	J01XX01	No	Reserve
Fusidic Acid	J01XC01	No	Access
Gentamicin	J01GB03	No	Access
Levofloxacin	J01MA12	Yes	Watch
Linezolid	J01XX08	No	Reserve
Lymecycline	J01AA04	No	Watch
Meropenem	J01DH02	Yes	Reserve
Metronidazole	J01XD01	No	Access
Minocycline	J01AA08	No	Watch
Moxifloxacin	J01MA14	Yes	Watch
Nitrofurantoin	J01XE01	No	Access
Norfloxacin	J01MA06	Yes	Watch
Ofloxacin	J01MA01	Yes	Watch
Oxytetracycline	J01AA06	No	Watch
Penicillin G	J01CE01	No	Access
Penicillin V	J01CE02	No	Access
Piperacillin	J01CA12	Yes	Watch
Piperacillin/Tazobactam	J01CR05	Yes	Access or Watch (depending on indication)
Pivmecillinam	J01CA08	No	Access
Sulfamethoxazole/Trimethoprim	J01EE01	No	Access
Tedizolid	J01XX11	No	Reserve
Teicoplanin	J01XA02	No	Watch
Telavancin	J01XA03	No	Watch
Telithromycin	J01FA15	No	Watch
Temocillin	J01CA17	No	Watch
Tetracycline	J01AA07	No	Access
Tigecycline	J01AA12	Yes	Reserve
Tinidazole	J01XD02	No	Access
Tobramycin	J01GB01	No	Watch
Trimethoprim	J01EA01	No	Access
Vancomycin	J01XA01	No	Access or Watch (depending on indication)
Vancomycin	A07AA09 <sup>3</sup>	No	Access or Watch (depending on indication)

<sup>&</sup>lt;sup>1</sup> Included in meta-regression models as its own category, separate from Access and separate from Watch antibiotics

<sup>&</sup>lt;sup>2</sup> Although second-generation cephalosporins were classified as broad-spectrum, Cefaclor was not as it is administered orally and is not well absorbed.

<sup>&</sup>lt;sup>3</sup>Though not absorbed, A07AA12 and A07AA09 are important (alternate) treatment options for *Clostridium difficile* and were retained as they accounted for 0.8% of total DDDs.

Table 4: Number of Acute/General Medical Admissions in 135 Acute Care NHS Hospital Trusts, England, April 2010 to March 2017

NHS Acute Care Hospital Trust	Admissions (N=36,124,372)
Barts Health NHS Trust	655,728 (1.82%)
Heart of England NHS Foundation Trust	600,781 (1.66%)
University Hospitals of Leicester NHS Trust	592,378 (1.64%)
King's College Hospital NHS Foundation Trust	577,624 (1.60%)
Pennine Acute Hospitals NHS Trust	563,816 (1.56%)
Sheffield Teaching Hospitals NHS Foundation Trust	563,268 (1.56%)
Leeds Teaching Hospitals NHS Trust	535,954 (1.48%)
University Hospital of North Midlands NHS Trust	515,228 (1.43%)
East Kent Hospitals University NHS Foundation Trust	500,870 (1.39%)
The Royal Wolverhampton NHS Trust	497,593 (1.38%)
Shrewsbury and Telford Hospital NHS Trust	478,043 (1.32%)
Nottingham University Hospitals NHS Trust	475,821 (1.32%)
Imperial College Healthcare NHS Trust	455,868 (1.26%)
Royal Devon and Exeter NHS Foundation Trust	442,324 (1.22%)
Norfolk and Norwich University Hospitals NHS Foundation Trust	439,213 (1.22%)
University College London NHS Foundation Trust	431,899 (1.20%)
Oxford University Hospitals NHS Foundation Trust	431,286 (1.19%)
Royal Free London NHS Foundation Trust	424,790 (1.18%)
Frimley Health NHS Foundation Trust	423,701 (1.17%)
London North West Healthcare NHS Trust	422,383 (1.17%)
The Newcastle Upon Tyne Hospitals NHS Foundation Trust	415,388 (1.15%)
South Tees Hospitals NHS Foundation Trust	397,418 (1.10%)
Mid Yorkshire Hospitals NHS Trust	387,113 (1.07%)
York Teaching Hospital NHS Foundation Trust	374,825 (1.04%)
The Dudley Group NHS Foundation Trust	372,312 (1.03%)
Northumbria Healthcare NHS Foundation Trust	371,996 (1.03%)
Barking, Havering and Redbridge University Hospitals NHS Trust	366,606 (1.01%)
East Lancashire Hospitals NHS Trust	364,950 (1.01%)
County Durham and Darlington NHS Foundation Trust	355,572 (0.98%)
Royal Cornwall Hospitals NHS Trust	355,337 (0.98%)
Hull and East Yorkshire Hospitals NHS Trust	352,449 (0.98%)
Central Manchester University Hospitals NHS Foundation Trust	346,302 (0.96%)
United Lincolnshire Hospitals NHS Trust	344,500 (0.95%)
The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust	341,723 (0.95%)
University Hospital Birmingham NHS Foundation Trust	337,519 (0.93%)
University Hospitals Coventry and Warwickshire NHS Trust	335,214 (0.93%)
Portsmouth Hospitals NHS Trust	330,267 (0.91%)
University Hospital Southampton NHS Foundation Trust	329,881 (0.91%)
Gloucestershire Hospitals NHS Foundation Trust	326,409 (0.90%)
Derby Teaching Hospitals NHS Foundation Trust	325,309 (0.90%)

NHS Acute Care Hospital Trust	Admissions (N=36,124,372)
Western Sussex Hospitals NHS Foundation Trust	323,149 (0.89%)
Cambridge University Hospitals NHS Foundation Trust	317,725 (0.88%)
St George's University Hospitals NHS Foundation Trust	310,309 (0.86%)
Aintree University Hospital NHS Foundation Trust	304,050 (0.84%)
Worcestershire Acute Hospitals NHS Trust	302,599 (0.84%)
Royal Liverpool and Broadgreen University Hospitals NHS Trust	295,000 (0.82%)
Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust	293,277 (0.81%)
Sandwell and West Birmingham Hospitals NHS Trust	290,692 (0.80%)
Bradford Teaching Hospitals NHS Foundation Trust	290,347 (0.80%)
Guy's and St Thomas' NHS Foundation Trust	288,611 (0.80%)
Wirral University Teaching Hospital NHS Foundation Trust	279,952 (0.77%)
Lancashire Teaching Hospitals NHS Foundation Trust	276,100 (0.76%)
Blackpool Teaching Hospitals NHS Foundation Trust	272,910 (0.76%)
Brighton and Sussex University Hospitals NHS Trust	272,827 (0.76%)
East Sussex Healthcare NHS Trust	265,799 (0.74%)
Hampshire Hospitals NHS Foundation Trust	262,829 (0.73%)
North Tees and Hartlepool NHS Foundation Trust	262,443 (0.73%)
University Hospitals Bristol NHS Foundation Trust	255,811 (0.71%)
Maidstone and Tunbridge Wells NHS Trust	255,481 (0.71%)
Salford Royal NHS Foundation Trust	255,241 (0.71%)
West Hertfordshire Hospitals NHS Trust	252,202 (0.70%)
Chelsea and Westminster Hospital NHS Foundation Trust	250,648 (0.69%)
Royal United Hospitals Bath NHS Foundation Trust	244,224 (0.68%)
North Bristol NHS Trust	243,843 (0.68%)
Basildon and Thurrock University Hospitals NHS Foundation Trust	243,711 (0.67%)
Northern Lincolnshire and Goole NHS Foundation Trust	243,420 (0.67%)
Calderdale and Huddersfield NHS Foundation Trust	238,032 (0.66%)
Plymouth Hospitals NHS Trust	236,544 (0.65%)
St Helens and Knowsley Teaching Hospitals NHS Trust	235,402 (0.65%)
Southend University Hospital NHS Foundation Trust	233,632 (0.65%)
Ipswich Hospital NHS Trust	229,172 (0.63%)
Royal Berkshire NHS Foundation Trust	226,441 (0.63%)
University Hospitals of Morecambe Bay NHS Foundation Trust	225,491 (0.62%)
Colchester Hospital University NHS Foundation Trust	225,100 (0.62%)
City Hospitals Sunderland NHS Foundation Trust	224,731 (0.62%)
University Hospital of South Manchester NHS Foundation Trust	224,210 (0.62%)
Great Western Hospitals NHS Foundation Trust	216,419 (0.60%)
Wrightington, Wigan and Leigh NHS Foundation Trust	216,327 (0.60%)
Epsom and St Helier University Hospitals NHS Trust	215,461 (0.60%)
Sherwood Forest Hospitals NHS Foundation Trust	213,972 (0.59%)
Kettering General Hospital NHS Foundation Trust	213,856 (0.59%)
North Cumbria University Hospitals NHS Trust	207,188 (0.57%)

NHS Acute Care Hospital Trust	Admissions (N=36,124,372)
Stockport NHS Foundation Trust	204,489 (0.57%)
The Lewisham and Greenwich NHS Trust	204,330 (0.57%)
Torbay and South Devon Health Care NHS Foundation Trust	204,304 (0.57%)
Taunton and Somerset NHS Foundation Trust	203,272 (0.56%)
Buckinghamshire Healthcare NHS Trust	199,735 (0.55%)
Northampton General Hospital NHS Trust	198,621 (0.55%)
Mid Essex Hospital Services NHS Trust	196,750 (0.54%)
Surrey and Sussex Healthcare NHS Trust	195,349 (0.54%)
Luton and Dunstable University Hospital NHS Foundation Trust	195,087 (0.54%)
Gateshead Health NHS Foundation Trust	192,158 (0.53%)
East and North Hertfordshire NHS Trust	191,475 (0.53%)
Chesterfield Royal Hospital NHS Foundation Trust	190,801 (0.53%)
The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust	190,063 (0.53%)
Bolton NHS Foundation Trust	188,364 (0.52%)
Barnsley Hospital NHS Foundation Trust	181,844 (0.50%)
Poole Hospital NHS Foundation Trust	179,480 (0.50%)
Walsall Healthcare NHS Trust	178,890 (0.50%)
Ashford and St. Peter's Hospitals NHS Foundation Trust	176,576 (0.49%)
Peterborough and Stamford Hospitals NHS Foundation Trust	173,905 (0.48%)
Medway NHS Foundation Trust	169,650 (0.47%)
The Princess Alexandra Hospital NHS Trust	167,726 (0.46%)
The Rotherham NHS Foundation Trust	165,268 (0.46%)
North Middlesex University Hospital NHS Trust	160,818 (0.45%)
Warrington and Halton Hospitals NHS Foundation Trust	159,990 (0.44%)
James Paget University Hospitals NHS Foundation Trust	157,301 (0.44%)
Croydon Health Services NHS Trust	156,603 (0.43%)
Southport and Ormskirk Hospital NHS Trust	155,726 (0.43%)
Milton Keynes Hospital NHS Foundation Trust	152,350 (0.42%)
The Mid Cheshire Hospitals NHS Foundation Trust	151,949 (0.42%)
Tameside Hospital NHS Foundation Trust	150,714 (0.42%)
Dartford and Gravesham NHS Trust	150,517 (0.42%)
Bedford Hospital NHS Trust	148,377 (0.41%)
Kingston Hospital NHS Foundation Trust	147,291 (0.41%)
Burton Hospitals NHS Foundation Trust	144,039 (0.40%)
Airedale NHS Foundation Trust	142,587 (0.39%)
Salisbury NHS Foundation Trust	139,310 (0.39%)
Homerton University Hospital NHS Foundation Trust	138,945 (0.38%)
The Hillingdon Hospitals NHS Foundation Trust	138,454 (0.38%)
Dorset County Hospital NHS Foundation Trust	131,000 (0.36%)
South Warwickshire NHS Foundation Trust	130,656 (0.36%)
West Suffolk NHS Foundation Trust	129,822 (0.36%)
Northern Devon Healthcare NHS Trust	127,192 (0.35%)

NHS Acute Care Hospital Trust	Admissions (N=36,124,372)
Countess of Chester Hospital NHS Foundation Trust	124,431 (0.34%)
Royal Surrey County Hospital NHS Foundation Trust	120,376 (0.33%)
South Tyneside NHS Foundation Trust	120,055 (0.33%)
The Whittington Hospital NHS Trust	117,822 (0.33%)
Harrogate and District NHS Foundation Trust	113,270 (0.31%)
Hinchingbrooke Health Care NHS Trust	103,636 (0.29%)
Yeovil District Hospital NHS Foundation Trust	103,543 (0.29%)
George Eliot Hospital NHS Trust	94,417 (0.26%)
East Cheshire NHS Trust	93,900 (0.26%)
Weston Area Health NHS Trust	89,741 (0.25%)
Wye Valley NHS Trust	86,567 (0.24%)

Table 5: Clinical Classifications Software (CCS) Diagnosis Group Identified among Acute/General Medical Admissions in 135 Acute Care NHS Hospital Trusts, England, April 2010 to March 2017

CCS diagnosis groups collapsed into 29 categories	Admissions (N=36,124,372)
Nonspecific chest pain; Cardiac dysrhythmias; Coronary atherosclerosis and other	
heart disease; Pulmonary heart disease; Essential hypertension, Hypertension with	
complications and secondary hypertension; Peri-, endo-, and myocarditis;	
cardiomyopathy (except that caused by tuberculosis or sexually transmitted disease);	
Conduction disorders; Heart valve disorders; Cardiac arrest and ventricular	
fibrillation; Other and ill-defined heart disease; Other circulatory disease	4,649,241 (12.87%)
Cancer of bladder; Cancer of bone and connective tissue, Cancer of thyroid,	
Malignant neoplasm without specification of site; Cancer of brain and nervous	
system; Cancer of breast; Cancer of bronchus, lung; Cancer of cervix, Cancer of	
other female genital organs; Cancer of colon; Cancer of head and neck; Cancer of	
kidney and renal pelvis, Cancer of other urinary organs; Cancer of liver and	
intrahepatic bile duct; Cancer of oesophagus; Cancer of other GI organs,	
peritoneum; Cancer of ovary; Cancer of pancreas; Cancer of prostate, Cancer of	
testis, Cancer of other male genital organs; Cancer of rectum and anus; Cancer of	
stomach; Cancer of uterus; Cancer, other and unspecified primary, Maintenance	
chemotherapy; radiotherapy; Cancer, other respiratory and intrathoracic; Hodgkin's	
disease, Non-Hodgkin's lymphoma; Leukemias; Melanomas of skin, Other non-	
epithelial cancer of skin; Multiple myeloma; Neoplasms of unspecified nature or	
uncertain behavior, Nonmalignant breast conditions; Pathological fracture;	
Secondary malignancies	3,848,695 (10.65%)
Headache; including migraine, Cataract, Retinal detachments; defects; vascular	
occlusion; and retinopathy, Glaucoma, Blindness and vision defects, Inflammation;	
infection of eye (except that caused by tuberculosis or sexually transmitted disease),	
Other eye disorders, Otitis media and related conditions, Conditions associated with	
dizziness or vertigo, Other ear and sense organ disorders; Syncope; Epilepsy;	
convulsions; Other nervous system disorders; Malaise and fatigue; Multiple	
sclerosis, Other hereditary and degenerative nervous system conditions; Parkinson's	
disease; Paralysis, Late effects of cerebrovascular disease	2,520,624 (6.98%)
Regional enteritis and ulcerative colitis; Diverticulosis & diverticulitis, Anal and	
rectal conditions; Noninfectious gastroenteritis; Abdominal pain; Abdominal hernia;	
Intestinal obstruction without hernia; Appendicitis and other appendiceal conditions,	
Peritonitis and intestinal abscess	2,288,317 (6.33%)
Other gastrointestinal disorders; Gastritis & duodenitis, Other disorders of stomach	,
and duodenum; Gastroduodenal ulcer (except hemorrhage)	2,062,927 (5.71%)
Deficiency and other anemia, Acute posthemorrhagic anemia; Nutritional	, , , , ,
deficiencies, Disorders of lipid metabolism, Other nutritional; endocrine; and	
metabolic disorders; Diseases of white blood cells	1,779,260 (4.93%)
Allergic reactions, Rehabilitation care; fitting of prostheses; and adjustment of	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
devices, Administrative/social admission, Medical examination/evaluation, Other	
aftercare, Other screening for suspected conditions (not mental disorders or	
infectious disease), Residual codes; unclassified, E Codes: All (external causes of	
injury and poisoning); Poisoning by psychotropic agents, Poisoning by other	
medications and drugs, Poisoning by nonmedicinal substances	1,755,860 (4.86%)
Esophageal disorders; Gastrointestinal hemorrhage	1,546,058 (4.28%)

CCS diagnosis groups collapsed into 29 categories	Admissions (N=36,124,372)
Other connective tissue disease; Gout and other crystal arthropathies, Rheumatoid	
arthritis and related disease, Osteoarthritis, Acquired foot deformities, Other	
acquired deformities, Systemic lupus erythematosus and connective tissue disorders,	
Other bone disease and musculoskeletal deformities; Other non-traumatic joint	
disorders	1,530,254 (4.24%)
Pneumonia (except that caused by tuberculosis or sexually transmitted disease);	
Aspiration pneumonitis; food/vomitus	1,392,396 (3.85%)
Chronic obstructive pulmonary disease and bronchiectasis; Cystic fibrosis, Other	
lower respiratory disease; Lung disease due to external agents	1,228,385 (3.40%)
Other, outcome risk above overall risk	1,148,971 (3.18%)
Other, outcome risk is below overall risk	1,058,630 (2.93%)
Urinary tract infections; Genitourinary symptoms and ill-defined conditions	838,968 (2.32%)
Acute cerebrovascular disease; Occlusion or stenosis of precerebral arteries, Other and ill-defined cerebrovascular disease, Transient cerebral ischemia; Coma; stupor;	
and brain damage	805,434 (2.23%)
Acute bronchitis; Asthma;	756,552 (2.09%)
Nephritis; nephrosis; renal sclerosis, Chronic renal failure; Calculus of urinary tract, Other diseases of kidneys and ureters, Other diseases of bladder and urethra	754,331 (2.09%)
Other liver diseases; Biliary tract disease; Liver disease; alcohol-related; Pancreatic	70 1,001 (2.0070)
disorders (not diabetes)	646,577 (1.79%)
Mental retardation, Senility and organic mental disorders; Alcohol-related mental disorders, Substance-related mental disorders, Affective disorders, Anxiety; somatoform; dissociative; and personality disorders; Other psychoses;	
Schizophrenia and related disorders, Preadult disorders, Other mental conditions, Personal history of mental disorder	641,475 (1.78%)
Superficial injury; contusion; Open wounds of head; neck; and trunk; Crushing	0.11,170 (117070)
injury or internal injury; Fracture of upper limb; Intracranial injury; Other injuries &	1
conditions due to external causes; Open wounds of extremities; Fracture of lower	1
limb; Fracture of neck of femur (hip); Burns	637,873 (1.77%)
Skin and subcutaneous tissue infections; Other inflammatory condition of skin, Chronic ulcer of skin, Other skin disorders	559,582 (1.55%)
Acute myocardial infarction  Spondylosis; intervertebral disc disorders; other back problems, Osteoporosis; Joint disorders and dislocations; trauma-related, Spinal cord injury, Skull and face	498,736 (1.38%)
fractures, Other fractures, Sprains and strains	481,424 (1.33%)
-	
Low risk (probability of outcome <0.5%)	478,387 (1.32%)
Immunity disorders, Sickle cell anemia, Coagulation and hemorrhagic disorders,	450.054 (1.070/)
Other hematologic conditions	458,254 (1.27%)
Influenza, Acute and chronic tonsillitis, Other upper respiratory infections, Other upper respiratory disease, Disorders of teeth and jaw, Diseases of mouth; excluding	
dental	456,453 (1.26%)
Congestive heart failure; nonhypertensive	454,455 (1.26%)
Intestinal infection	442,769 (1.23%)
Phlebitis; thrombophlebitis and thromboembolism, Varicose veins of lower extremity, Hemorrhoids, Other disease of veins and lymphatics; Lymphadenitis, Gangrene; Peripheral and visceral atherosclerosis; Aortic and peripheral arterial	
embolism or thrombosis; Aortic; peripheral; and visceral artery aneurysms	403,484 (1.12%)

Table 6: Random effects meta-regression of the association between the adjusted probability of death within 30 days of admission (in/out of hospital) and different metrics of hospital-level antibiotic use, among 36,124,372 acute/general medicine admissions to 135 NHS acute care hospital Trusts, April 2010 – March 2017.

Metric of antibiotic use For each hospital-level increase of:	Change in the adjusted probability of 30-day mortality (95% CI) <sup>1</sup>	P-value
500 Total DDDs per 1000 bed-days	-0.010% (-0.064,+0.044)	0.718
500 Total DDDs per 1000 admissions	-0.021% (-0.044,+0.001)	0.065
500 Inpatient DDDs per 1000 bed-days	+0.004% (-0.076,+0.085)	0.917
500 Inpatient DDDs per 1000 admissions	-0.014% (-0.045,+0.017)	0.362
500 Outpatient DDD per 1000 bed-days	-0.021% (-0.081,+0.038)	0.483
500 Outpatient DDD per 1000 admissions	-0.020% (-0.049,+0.008)	0.161
500 Oral DDDs per 1000 bed-days	-0.029% (-0.087,+0.028)	0.316
500 Oral DDDs per 1000 admissions	-0.028% (-0.053,-0.003)	0.028
500 Parenteral DDDs per 1000 bed-days	+0.284% (+0.031,+0.538)	0.028
500 Parenteral DDDs per 1000 admissions	+0.040% (-0.065,+0.145)	0.454
500 Narrow-spectrum DDDs per 1000 bed-days	-0.025% (-0.096,+0.046)	0.483
500 Narrow-spectrum DDDs per 1000 admissions	-0.026% (-0.055,+0.003)	0.074
500 Broad-spectrum DDDs per 1000 bed-days	+0.012% (-0.101,+0.125)	0.836
500 Broad-spectrum DDDs per 1000 admissions	-0.019% (-0.072,+0.034)	0.475
500 Access DDDs per 1000 bed-days	-0.033% (-0.126,+0.059)	0.476
500 Access DDDs per 1000 admissions	-0.032% (-0.072,+0.007)	0.102
500 Watch DDDs per 1000 bed-days	+0.035% (-0.083,+0.152)	0.561
500 Watch DDDs per 1000 admissions	-0.009% (-0.065,+0.047)	0.751
500 Access or Watch (depending on indication) DDDs per 1000 bed-days	-0.091% (-0.272,+0.090)	0.323
500 Access or Watch (depending on indication) DDDs per 1000 admissions	-0.078% (-0.157,+0.000)	0.050
100 Reserve DDDs per 1000 bed-days	-0.027% (-0.240,+0.186)	0.800
100 Reserve DDDs per 100 per 1000 admissions	-0.046% (-0.131,+0.040)	0.293
100 Piperacillin/tazobactam and meropenem DDDs per 1000 bed-days	+0.002% (-0.143,+0.147)	0.978
100 Piperacillin/tazobactam and meropenem DDDs per 1000 admissions	-0.023% (-0.085,+0.039)	0.464

<sup>&</sup>lt;sup>1</sup> Probability of death derived from 135 separate (hospital-specific) Poisson models, with each model adjusting for all the factors in Table 1 (main text). Plots for each model are displayed in Appendix Figure 3.

Table 7: Random effects meta-regression of the association between the adjusted probability of death within 30 days of admission (in/out of hospital) and different metrics of hospital-level antibiotic use, among a more narrowly defined cohort of 19,023,144 acute/general medicine admissions, April 2010 – March 2017.

Metric of antibiotic use For each hospital-level increase of:	Change in the adjusted probability of 30-day mortality (95% CI) <sup>1</sup>	P-value
500 Total DDDs per 1000 bed-days	+0.006% (-0.058,+0.071)	0.844
500 Total DDDs per 1000 admissions	-0.007% (-0.034,+0.020)	0.626
500 Inpatient DDDs per 1000 bed-days	+0.042% (-0.051,+0.136)	0.374
500 Inpatient DDDs per 1000 admissions	+0.005% (-0.031,+0.041)	0.779
500 Outpatient DDD per 1000 bed-days	-0.021% (-0.092,+0.050)	0.557
500 Outpatient DDD per 1000 admissions	-0.016% (-0.049,+0.017)	0.343
500 Oral DDDs per 1000 bed-days	-0.017% (-0.087,+0.053)	0.630
500 Oral DDDs per 1000 admissions	-0.016% (-0.046,+0.014)	0.299
500 Parenteral DDDs per 1000 bed-days	+0.373% (+0.082,+0.663)	0.012
500 Parenteral DDDs per 1000 admissions	+0.113% (-0.008,+0.235)	0.068
500 Narrow-spectrum DDDs per 1000 bed-days	-0.013% (-0.097,+0.071)	0.761
500 Narrow-spectrum DDDs per 1000 admissions	-0.014% (-0.048,+0.020)	0.431
500 Broad-spectrum DDDs per 1000 bed-days	+0.066% (-0.069,+0.201)	0.337
500 Broad-spectrum DDDs per 1000 admissions	+0.017% (-0.046,+0.080)	0.592
500 Access DDDs per 1000 bed-days	-0.027% (-0.137,+0.082)	0.624
500 Access DDDs per 1000 admissions	-0.019% (-0.065,+0.027)	0.407
500 Watch DDDs per 1000 bed-days	+0.078% (-0.063,+0.218)	0.276
500 Watch DDDs per 1000 admissions	+0.022% (-0.044,+0.089)	0.508
500 Access or Watch (depending on indication) DDDs per 1000 bed-days	-0.042% (-0.258,+0.173)	0.698
500 Access or Watch (depending on indication) DDDs per 1000 admissions	-0.038% (-0.133,+0.056)	0.426
100 Reserve DDDs per 1000 bed-days	+0.206% (-0.037,+0.450)	0.096
100 Reserve DDDs per 100 per 1000 admissions	+0.055% (-0.043,+0.154)	0.270
100 Piperacillin/tazobactam and meropenem DDDs per 1000 bed-days	+0.096% (-0.072,+0.265)	0.260
100 Piperacillin/tazobactam and meropenem DDDs per 1000 admissions	+0.026% (-0.047,+0.099)	0.486

<sup>&</sup>lt;sup>1</sup>To improve model stability, five hospital Trusts with fewer than 50,000 admissions were excluded, including City Hospitals Sunderland NHS Foundation Trust, Harrogate and District NHS Foundation Trust, Royal Surrey County Hospital NHS Foundation Trust, The Hillingdon Hospitals NHS Foundation Trust, and The Whittington Hospital NHS Trust. Thus, the probability of death was derived from 130 separate (hospital-specific) Poisson models, with each model adjusting for all the factors in Table 1 (main text) excluding admission specialty. Two out of 130 models required the removal of an interaction term between admission method and admission year in order for the model to converge.

Table 8: Random effects meta-regression of the association between the adjusted probability of death within 30 days of admission (in/out of hospital) and different metrics of hospital-level antibiotic use, among 16,492,990 acute/general medicine admissions, 01/April/2014 – 31/March/2017.

Metric of antibiotic use	Change in the adjusted probability of re-	P-value
For each hospital-level increase of:	admissions (95% CI) <sup>1</sup>	
500 Total DDDs per 1000 bed-days	+0.013 (-0.053,+0.080)	0.691
500 Total DDDs per 1000 admissions	+0.005 (-0.023,+0.034)	0.713
500 Inpatient DDDs per 1000 bed-days	+0.061 (-0.039,+0.160)	0.231
500 Inpatient DDDs per 1000 admissions	+0.021 (-0.017,+0.060)	0.281
500 Outpatient DDD per 1000 bed-days	-0.020 (-0.093,+0.054)	0.592
500 Outpatient DDD per 1000 admissions	-0.009 (-0.044,+0.026)	0.612
500 Oral DDDs per 1000 bed-days	+0.029 (-0.090,+0.148)	0.634
500 Oral DDDs per 1000 admissions	+0.003 (-0.028,+0.035)	0.848
500 Parenteral DDDs per 1000 bed-days	+0.160 (-0.161,+0.481)	0.326
500 Parenteral DDDs per 1000 admissions	+0.075 (-0.057,+0.207)	0.261
500 Narrow-spectrum DDDs per 1000 bed-days	-0.001 (-0.090,+0.088)	0.979
500 Narrow-spectrum DDDs per 1000 admissions	+0.002 (-0.034,+0.039)	0.908
500 Broad-spectrum DDDs per 1000 bed-days	+0.063 (-0.077,+0.204)	0.373
500 Broad-spectrum DDDs per 1000 admissions	+0.031 (-0.034,+0.096)	0.353
500 Access DDDs per 1000 bed-days	-0.025 (-0.142,+0.093)	0.678
500 Access DDDs per 1000 admissions	-0.004 (-0.053,+0.046)	0.886
500 Watch DDDs per 1000 bed-days	+0.092 (-0.054,+0.238)	0.214
500 Watch DDDs per 1000 admissions	+0.043 (026,+0.112)	0.215
500 Access or Watch (depending on indication) DDDs per 1000 bed-days	+0.026 (-0.198,+0.250)	0.818
500 Access or Watch (depending on indication) DDDs per 1000 admissions	+0.012 (-0.087,+0.111)	0.811
100 Reserve DDDs per 1000 bed-days	-0.033 (-0.303,+0.238)	0.812
100 Reserve DDDs per 100 per 1000 admissions	-0.023 (-0.131,+0.084)	0.666
100 Piperacillin/tazobactam and meropenem DDDs per 1000 bed-days	+0.001 (-0.180,+0.181)	0.994
100 Piperacillin/tazobactam and meropenem DDDs per 1000 admissions	+0.002 (-0.075,+0.080)	0.952

<sup>&</sup>lt;sup>1</sup>To improve model stability, four hospital Trusts with fewer than 50,000 admissions were excluded, including East Cheshire NHS Trust, George Eliot Hospital NHS Trust, Weston Area Health NHS Trust, and Wye Valley NHS Trust. Royal Surrey County Hospital was also excluded as it had just nine admissions in the reference group of admission specialty. City Hospitals Sunderland was excluded as it had no remaining admissions in the reference group of admission specialty. The probability of death was therefore derived from 129 separate (hospital-specific) Poisson models, with each model adjusting for all the factors in Table 1 (main text). Charlson comorbidity index and IMD score were modelled as linear predictors, rather than using natural cubic splines, as the use of splines led to poorly fitting models or the failure of models to converge.

Table 9: Random effects meta-regression of the association between the adjusted probability of death within 14 days of admission (in/out of hospital) and different metrics of hospital-level antibiotic use, among 36,124,372 acute/general medicine admissions, 01/April/2010 – 31/March/2017.

Metric of antibiotic use For each hospital-level increase of:	Change in the adjusted probability of re- admissions (95% CI) <sup>1</sup>	P-value
500 Total DDDs per 1000 bed-days	-0.009% (-0.054,+0.037)	0.699
500 Total DDDs per 1000 admissions	-0.019% (-0.038,-0.000)	0.047
500 Inpatient DDDs per 1000 bed-days	+0.003% (-0.065,+0.071)	0.928
500 Inpatient DDDs per 1000 admissions	-0.014% (-0.040,+0.012)	0.290
500 Outpatient DDD per 1000 bed-days	-0.015% (-0.065,+0.036)	0.564
500 Outpatient DDD per 1000 admissions	-0.016% (-0.040,+0.008)	0.186
500 Oral DDDs per 1000 bed-days	-0.027% (-0.076,+0.022)	0.273
500 Oral DDDs per 1000 admissions	-0.026% (-0.046,-0.005)	0.016
500 Parenteral DDDs per 1000 bed-days	+0.267% (+0.054,+0.479)	0.014
500 Parenteral DDDs per 1000 admissions	+0.039% (-0.050,+0.128)	0.384
500 Narrow-spectrum DDDs per 1000 bed-days	-0.025% (-0.085,+0.035)	0.412
500 Narrow-spectrum DDDs per 1000 admissions	-0.026% (-0.050,-0.002)	0.036
500 Broad-spectrum DDDs per 1000 bed-days	+0.023% (-0.072,+0.119)	0.630
500 Broad-spectrum DDDs per 1000 admissions	-0.011% (-0.055,+0.034)	0.639
500 Access DDDs per 1000 bed-days	-0.034% (-0.112,+0.044)	0.392
500 Access DDDs per 1000 admissions	-0.032% (-0.065,+0.000)	0.052
500 Watch DDDs per 1000 bed-days	+0.036% (-0.063,+0.135)	0.475
500 Watch DDDs per 1000 admissions	-0.007% (-0.054,+0.041)	0.784
500 Access or Watch (depending on indication) DDDs per 1000 bed-days	-0.069% (-0.222,+0.083)	0.370
500 Access or Watch (depending on indication) DDDs per 1000 admissions	-0.064% (-0.130,+0.002)	0.056
100 Reserve DDDs per 1000 bed-days	+0.029% (-0.150,+0.208)	0.750
100 Reserve DDDs per 100 per 1000 admissions	-0.021% (-0.093,+0.051)	0.563
100 Piperacillin/tazobactam and meropenem DDDs per 1000 bed-days	-0.003% (-0.125,+0.120)	0.966
100 Piperacillin/tazobactam and meropenem DDDs per 1000 admissions	-0.022% (-0.075,+0.030)	0.399

<sup>&</sup>lt;sup>1</sup> Each model adjusting for all the factors in Table 1 (main text). However, 14 models would only converge with Charlson comorbidity index and IMD score modelled as linear predictors, rather than as natural cubic splines.

Table 10: Random effects meta-regression of the association between the adjusted probability of non-elective re-admission within 30 days of discharge and different metrics of hospital-level antibiotic use, among 34,427,698 acute/general medicine admissions discharged alive, 01/April/2010 – 28/February/2017.

Metric of antibiotic use For each hospital-level increase of:	Change in the adjusted probability of re- admissions (95% CI) <sup>1</sup>	P-value
500 Total DDDs per 1000 bed-days	+0.404 (+0.157, +0.652)	0.002
500 Total DDDs per 1000 admissions	+0.208 (+0.106,+0.311)	<0.001
500 Inpatient DDDs per 1000 bed-days	+0.149 (-0.234,+0.531)	0.443
500 Inpatient DDDs per 1000 admissions	+0.117 (-0.028,+0.261)	0.114
500 Outpatient DDD per 1000 bed-days	+0.380 (+0.103,+0.657)	0.008
500 Outpatient DDD per 1000 admissions	+0.213 (+0.082,+0.344)	0.002
500 Oral DDDs per 1000 bed-days	+0.448 (+0.183,+0.713)	0.001
500 Oral DDDs per 1000 admissions	+0.233 (+0.120,+0.345)	<0.001
500 Parenteral DDDs per 1000 bed-days	+0.431 (-0.793,+1.655)	0.488
500 Parenteral DDDs per 1000 admissions	+0.463 (-0.031,+0.956)	0.066
500 Narrow-spectrum DDDs per 1000 bed-days	+0.521 (+0.194,+0.848)	0.002
500 Narrow-spectrum DDDs per 1000 admissions	+0.254 (+0.124,+0.384)	<0.001
500 Broad-spectrum DDDs per 1000 bed-days	+0.514 (-0.018,+1.046)	0.058
500 Broad-spectrum DDDs per 1000 admissions	+0.330 (+0.085,+0.575)	0.009
500 Access DDDs per 1000 bed-days	+0.592 (+0.164,+1.021)	0.007
500 Access DDDs per 1000 admissions	+0.315 (+0.137,+0.493)	0.001
500 Watch DDDs per 1000 bed-days	+0.719 (+0.173,+1.266)	0.010
500 Watch DDDs per 1000 admissions	+0.437 (+0.181,+0.692)	0.001
500 Access or Watch (depending on indication) DDDs per 1000 bed-days	+0.697 (-0.161,+1.554)	0.110
500 Access or Watch (depending on indication) DDDs per 1000 admissions	+0.436 (+0.067,+0.806)	0.021
100 Reserve DDDs per 1000 bed-days	-0.162 (-1.175,+0.851)	0.753
100 Reserve DDDs per 100 per 1000 admissions	+0.028 (-0.385,+0.440)	0.894
100 Piperacillin/tazobactam and meropenem DDDs per 1000 bed-days	-0.109 (-0.800,+0.581)	0.755
100 Piperacillin/tazobactam and meropenem DDDs per 1000 admissions	+0.073 (-0.222,+0.368)	0.624

<sup>&</sup>lt;sup>1</sup>Each model adjusted for all the factors in Table 1 (main text). Charlson comorbidity score was modelled as a linear predictors, rather than using natural cubic splines, as the use of splines led to poorly fitting models or the failure of models to converge.

#### APPENDIX FIGURES

Figure 1: Order of Data Cleaning Steps Followed to Derive Analytic Cohort

n = 88,718,419 spells	
n = 88,693,859 spells	Dropped 24,560 spells with unfinished consultant episodes <sup>i</sup>
	Dropped 274 spells with missing discharge date
n = 88,693,585 spells	Dropped 1,577,400 spells from patients <16 years of age in all spells
n = 87,116,185 spells	Dropped 367,918 spells from patients missing age in all spells
n = 86,748,267 spells	Dropped 14,496 spells from patients with ≥10 ages recorded across all spells <sup>ii</sup>
n=86,733,771 spells	Dropped 25,866 spells from patients with >1 death dateiii
n = 86,707,905 spells	Dropped 3,444,789 spells from patients not admitted to general medicine (ever) <sup>iv</sup>
n = 83,263,116 spells <sup>v</sup>	Dropped 40,825,371 spells not in general medicineiv
n = 42,437,745 spells	
n = 42,381,516 spells	Dropped 56,229 spells <16 years of age at admission <sup>vi</sup>
	Dropped 4,540,135 admissions before 01 April 2010vii
n = 37,841,381 spells	Dropped 510,509 spells not in acute care hospital Trusts
n = 37,330,872 spells	Dropped 485,843 spells from hospital Trusts with <50,000 spells during study
n = 36,845,029 spells	
n = 36,578,060 spells	Dropped 266,969 spells missing IMD score
	Dropped 453,688 spells in specialist hospital Trusts <sup>viii</sup>
n = 36,124,372 spells	

<sup>&</sup>lt;sup>i</sup> These spells are duplicated across adjacent HES data-years and thus the duplicate was dropped(1)

<sup>&</sup>lt;sup>ii</sup> Raw data contained admissions between 2009-2017 (also see <sup>vii</sup> below). Patients with ≥10 ages recorded were dropped, as age was judged to be invalid.

iii If a patient was recorded to have died in >1 spell, the earliest date of death was retained and subsequent spells were dropped

iv Acute/general medicine defined as in Figure 1 (main text)


<sup>&</sup>lt;sup>v</sup> At this point, previous hospital exposure and re-admission after discharge were estimated, as all patients had at least 1 admission that met our inclusion criteria in Figure 1 (main text)

vi Among patients ever admitted ≥16 years of age

vii Admissions between 1 April 2009 to 31 March 2010 were used only to estimate previous hospital exposure for spells beginning from 01 April 2010

viii Includes one hospital Trust where most (84.9%) admissions were to clinical haematology (The Royal Marsden NHS Foundation Trust) and three hospital Trusts where all admissions were to either cardiology or respiratory medicine (Royal Brompton and Harefield NHS Foundation Trust, Papworth Hospital NHS Foundation Trust, and Liverpool Heart and Chest NHS Foundation Trust) – i.e. no admissions had a HES main specialty code (mainspef) or treatment specialty code (tretspef) equal to 300 in the first or second consultant episode

Figure 2: Non-linear Relative Risks of Death Within 30 Days of Admission (In/Out of Hospital) Among Model Covariates Fit As Natural Cubic Splines



Adjusted risk estimates derived from a single Poisson model containing NHS hospital Trust as a factor and all admission characteristics in Table 1 (main text).

Figure 3: Top 10 Most Commonly Used Antibiotics as a Fraction of Total DDDs Within Each of 135 NHS Acute Care Hospital Trusts (2016), Ranked by Amoxicillin/Clavulanic Acid








Figure 4: Random Effects Meta-Regression of the Association Between Adjusted Probability of Death Within 30 Days of Admission (In/Out of Hospital) and Hospital-level Antibiotic Use


# 4.1a) Total DDDs/1,000 bed-days\*




## 4.1b) Total DDDs/1,000 admissions\*




## 4.2a) Inpatient DDDs/1,000 bed-days\*




## 4.2b) Inpatient DDDs/1,000 admissions\*




## 4.3a) Outpatient DDDs/1,000 bed-days\*




## 4.3b) Outpatient DDDs/1,000 admissions\*




#### 4.4a) Oral DDDs/1,000 bed-days\*




#### 4.4b) Oral DDDs/1,000 admissions\*




#### 4.5a) Parenteral DDDs/1,000 bed-days\*




## 4.5b) Parenteral DDDs/1,000 admissions\*




### 4.6a) Narrow-spectrum DDDs/1,000 bed-days\*




## 4.6b) Narrow-spectrum DDDs/1,000 admissions\*




# 4.7a) Broad-spectrum DDDs/1,000 bed-days\*




## 4.7b) Broad-spectrum DDDs/1,000 admissions\*




#### 4.8a) Access DDDs/1,000 bed-days\*




#### 4.8b) Access DDDs/1,000 admissions\*




#### 4.9a) Watch DDDs/1,000 bed-days\*




## 4.9b) Watch DDDs/1,000 admissions\*




#### 4.10a) Access or Watch (depending on indication) DDDs/1,000 bed-days\*




## 4.10b) Access or Watch (depending on indication) DDDs/1,000 admissions\*




## 4.11a) Reserve DDDs/1,000 bed-days\*




## 4.11b) Reserve DDDs/1,000 admissions\*



#### 4.12a) Piperacillin/tazobactam and meropenem DDDs/1,000 bed-days\*



### 4.12b) Piperacillin/tazobactam and meropenem DDDs/1,000 admissions\*



<sup>\*</sup> Marginal effects were derived from 135 separate (hospital-specific) models, represented here as circles sized according to the precision of the estimate (inverse of the within-hospital variance). Most (127/135) hospital-specific multivariate models (grey circles) included four spline terms (for age, Charlson score, IMD score, and overnight admissions in the past year), however models for eight hospital Trusts (orange

circles) would only converge with two spline terms (age and overnight admissions in the past year). Antibiotic use was truncated below the 2.5 percentile and above the 95<sup>th</sup> percentile. Probability estimates were truncated above the 99<sup>th</sup> percentile.

#### REFERENCES

- 1. Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC). *Int J Epidemiol*. 2017;46(4):1093-1093i. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28338941
- 2. Health and Social Care Information Centre. Methodology to create provider and CIP spells from HES APC data. 2014. Available from: https://digital.nhs.uk/binaries/content/documents/corporate-website/publication-system/ci-hub/compendium-indicators/compendium-indicators/publicationsystem:cilandingasset%5B3%5D/publicationsystem:Attachments%5B12%5D/publicationsystem:attachmentResource
- 3. Public Health England. MRSA bacteraemia: annual data. Annual counts and rates of meticillin resistant Staphylococcus aureus (MRSA) bacteraemia by acute trust and clinical commissioning group (CCG). 2018. Available from: https://www.gov.uk/government/statistics/mrsa-bacteraemia-annual-data
- 4. NHS England. KH03 Guidance: Data Definitions. 2010. Available from: https://www.england.nhs.uk/statistics/statistical-work-areas/bed-availability-and-occupancy/
- 5. NHS Digital. Summary Hospital-level Mortality Indicator (SHMI) Indicator specification. Version 1.32. 2020. Available from: http://digital.nhs.uk/SHMI
- 6. Walker AS, Mason A, Quan TP, et al. Mortality risks associated with emergency admissions during weekends and public holidays: an analysis of electronic health records. *Lancet*. 2017 Jul 1;390(10089):62–72. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673617307821
- 7. NHS Digital. HES Data Dictionary Admitted Patient Care. 2018. Available from: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics/hospital-episode-statistics-data-dictionary
- 8. Harrell F. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Springer; 2015.
- 9. Freemantle N, Richardson M, Wood J, et al. Weekend hospitalization and additional risk of death: an analysis of inpatient data. *J R Soc Med.* 2012 Feb;105(2):74–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22307037
- 10. Harbord R, Higgins J. Meta-regression in Stata. *The Stata Journal*. 2008;8(4):493–519.
- 11. Greenland S, O'Rourke K. Meta-Analysis. In: Rothman K, Greenland S, Lash T, editors. Modern Epidemiology. 3rd ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2008. p. 652–82.
- 12. Thompson S, Higgins J. How should meta-regression analyses be undertaken and interpreted? *Stat Med.* 2002;21(11):1559–73.
- 13. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. *Stat Med.* 1995 Feb 28;14(4):395–411. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7746979
- 14. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses. *Stat Med*. 2009 Apr 30;29(12):1282–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19408255

- 15. Norton EC, Dowd BE, Maciejewski ML. Marginal Effects—Quantifying the Effect of Changes in Risk Factors in Logistic Regression Models. *JAMA*. 2019 Apr 2;321(13):1304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30848814
- 16. NHS Digital. Provider spells methodology: provider mapping files October 2019. 2019. Available from: https://digital.nhs.uk/data-and-information/publications/ci-hub/summary-hospital-level-mortality-indicator-shmi
- 17. NHS Digital. Hospital admitted patient care activity: provider level analysis. 2017. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity